- Home
- GNLX vs SOPH Comparison
GNLX vs SOPH Comparison
Compare GNLX & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- SOPH
- Stock Information
- Founded
- GNLX 2001
- SOPH 2011
- Country
- GNLX United States
- SOPH Switzerland
- Employees
- GNLX N/A
- SOPH N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- SOPH Health Care
- Exchange
- GNLX Nasdaq
- SOPH Nasdaq
- Market Cap
- GNLX 184.4M
- SOPH 206.6M
- IPO Year
- GNLX 2023
- SOPH 2021
- Fundamental
- Price
- GNLX $2.63
- SOPH $2.83
- Analyst Decision
- GNLX Strong Buy
- SOPH Strong Buy
- Analyst Count
- GNLX 4
- SOPH 2
- Target Price
- GNLX $18.25
- SOPH $6.50
- AVG Volume (30 Days)
- GNLX 233.3K
- SOPH 36.0K
- Earning Date
- GNLX 05-08-2025
- SOPH 05-06-2025
- Dividend Yield
- GNLX N/A
- SOPH N/A
- EPS Growth
- GNLX N/A
- SOPH N/A
- EPS
- GNLX N/A
- SOPH N/A
- Revenue
- GNLX $8,000.00
- SOPH $65,173,000.00
- Revenue This Year
- GNLX N/A
- SOPH $14.83
- Revenue Next Year
- GNLX N/A
- SOPH $22.79
- P/E Ratio
- GNLX N/A
- SOPH N/A
- Revenue Growth
- GNLX N/A
- SOPH 4.49
- 52 Week Low
- GNLX $1.60
- SOPH $2.60
- 52 Week High
- GNLX $5.89
- SOPH $6.28
- Technical
- Relative Strength Index (RSI)
- GNLX 42.31
- SOPH 42.78
- Support Level
- GNLX $2.30
- SOPH $2.60
- Resistance Level
- GNLX $2.68
- SOPH $3.00
- Average True Range (ATR)
- GNLX 0.26
- SOPH 0.32
- MACD
- GNLX 0.05
- SOPH -0.00
- Stochastic Oscillator
- GNLX 55.49
- SOPH 25.84
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.